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Abstract
Background Oral rehydration therapy is the recommended
treatment for acute childhood gastroenteritis. The aim of
this study was to assess the efficacy and safety of gelatin
tannate plus oral rehydration compared with oral rehydra-
tion alone.
Methods We conducted a multicenter, parallel, random-
ized, controlled, single-blind, prospective, open-label trial.
A central randomization center used computer generated
tables to allocate treatments. The study was performed in
two medical centers in Italy. Sixty patients 3–72 months of
age with acute gastroenteritis were recruited (median age
18 months; age range 3–66 months): 29 received an oral
rehydration solution (ORS) and 31 an ORS plus gelatin
tannate (ORS ? G). The primary outcome was the number
of bowel movements 48 and 72 h after initiating treatment.
Secondary outcomes were: duration of diarrhea, stool
characteristics and adverse events.
Results No patient was lost at follow-up. No significant
difference in the number of bowel movements after 48 h
was reported (2.7 ± 1.3 ORS ? G; 3.2 ± 0.8 ORS;
p = 0.06), although the ORS ? G group showed a sig-
nificant improvement in stool consistency (3.7 ± 1.0 vs.
4.3 ± 0.8; p = 0.005). At 72 h, a significant reduction in
bowel movements was reported in the ORS ? G group
compared with the ORS group (1.0 ± 1.4 vs. 2.0 ± 1.7;
p = 0.01). Mean duration of diarrhea was significantly
lower in the ORS ? G group than in the ORS only group
(76.8 ± 19.2 vs. 108 ± 24.0 h; p\ 0.0001). No adverse
events were reported.
Conclusions Gelatin tannate added to oral rehydration in
children with acute diarrhea was associated with a signif-
icant decrease in bowel movements at 72 h, with an early
improvement in the stool consistency and shorter disease
duration.
Clinical Trial Registration NCT02644200—Gelatin Tan-
nate as Treatment for Acute Childhood Gastroenteritis
(https://www.clinicaltrials.gov).
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Oral rehydration therapy is the main treatment
recommended for acute gastroenteritis. Recently,
gelatin tannate has been proposed as a theoretically
effective new treatment. Clinical data on its efficacy
are very limited.
This is the first single-blind, prospective,
randomized, parallel study in children that
demonstrates that gelatin tannate can be effective,
well-tolerated, and safe in addition to oral
rehydration therapy.
1 Background
Acute gastroenteritis is one of the most common diseases
in childhood, with up to 3–5 billion cases of acute gas-
troenteritis and nearly 2 million deaths per year in children
under 5 years. It is also a significant healthcare burden both
in developing and developed countries [1]. According to
the European Society for Paediatric Gastroenterology,
Hepatology and Nutrition (ESPGHAN) guidelines for the
treatment of acute gastroenteritis, oral rehydration with
hypo-osmolar solutions is the mainstay of therapy [2].
However, although rehydration therapy has achieved a
significant reduction in mortality and morbidity due to
dehydration, it does not affect the duration of diarrhea
[3, 4]. Therefore, active treatments that may impact on the
severity of diarrhea have been implemented, including
specific probiotics, such as Lactobacillus GG or Saccha-
romyces boulardii or drugs such as racecadotril or dios-
mectite [5–7].
Recently, gelatin tannate, a compound based on tannic
acid suspension in a gelatin solution, has been proposed as
a theoretically effective treatment for pediatric acute gas-
troenteritis [8]. Tannins are mostly water-soluble phenolic
compounds, and are well-known antioxidants sourced from
medicinal plants, foods, and edible fruits. Vegetable tan-
nins have attracted a lot of attention in recent years because
of their multifunctional properties, beneficial to human
health, demonstrated through in vitro and in vivo assays,
and recently, an antidiarrhoic effect of gelatin tannate has
been reported [9, 10]. Scaldaferri et al. evaluated the
therapeutic effect and mechanisms of action of gelatin
tannate using the dextran sulfate sodium (DSS)-induced
acute colitis mouse model. Gelatin tannate not only sig-
nificantly improved disease severity in terms of disease
activity index (DAI), but also body weight and histological
score [11].
Furthermore, gelatin tannate has been reported to mod-
ulate the composition of gut microbiota, restore mucus
layer, with an improvement of gut permeability, and exert a
direct anti-inflammatory effect in the gastrointestinal
mucosa [12, 13]. Clinical data on the efficacy of gelatin
tannate in acute gastroenteritis are very limited. In 2009,
Esteban Carretero et al. reported a significant reduction in
the number of loose stools in 97 children treated with oral
rehydration solution (ORS) plus gelatin tannate
(ORS ? G), compared with 114 treated with ORS alone in
a non-randomized, non-blinded clinical study [10]. No
drug-related adverse events were reported. More recently, a
randomized, blinded, placebo-controlled trial was per-
formed in 40 adults with acute diarrhea [14]. A significant
reduction in the number of loose stools was reported in the
active group compared with placebo. Based on these two
studies, a systematic review on the efficacy of gelatin
tannate in acute gastroenteritis published in 2014 con-
cluded that there is not enough evidence to support the use
of gelatin tannate in clinical practice [15].
The aim of this study was to evaluate the efficacy and
safety of gelatin tannate combined with ORS compared
with ORS in children with acute gastroenteritis.
2 Methods
This was a single-blind, prospective, randomized, parallel
study conducted in two pediatric services of two tertiary-
care hospitals.
Children were eligible for the study if they were
3–72 months of age with acute gastroenteritis, as defined
by having at least three loose stools within the previous
24 h and/or a change in stool consistency to loose or liquid
according to the modified Bristol Stool Form Scale for
Children (m-BSFS-C) lasting for no longer than 3 days
[16, 17]. Patients with gastroenteritis for more than 3 days,
those with chronic gastrointestinal diseases, or those
receiving other antidiarrheal drugs within 2 weeks prior to
enrollment (i.e., antibiotics, probiotics, salicylates, lop-
eramide, racecadotril, diosmectite) were excluded from the
study.
All children were randomly assigned to the groups using
a computer-generated randomization list. The sequence
was concealed and envelopes for consecutive patients
prepared accordingly. As each patient was recruited, the
next envelope in sequence was opened to determine the
allocation of the patient. Group 1 received ORS (controls)
and group 2 received ORS plus gelatin tannate (Gelen-
terum sachet 250 mg, manufactured by Novintethical
Pharma Sagl, Lugano, Switzerland, marketed by ACRAF
S.p.A Italy) as follows: 250 mg every 6 h if weighing less
than 15 kg and 500 mg every 6 h if weighing over 15 kg,
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for 5 days. Allocation and management of enrolled patients
were performed by two physicians (M.M. and C.T.), while
the study coordinator (M.A.) was blinded to the group
allocation and the treatment received until the completion
of the trial.
Patients in both treatment groups received a standard
rehydration solution, following the recommendations of the
ESPGHAN [2].
During the initial visit, the following data were col-
lected: demographic variables, family history of gastroin-
testinal disease, patient’s medical history and
characteristics of the current gastroenteritis. Physical ex-
amination was performed, collecting data on weight, body
temperature, heart and respiration rates, blood pressure,
degree of dehydration, and any additional tests required for
clinical purposes by the treating physician. Dehydration
was evaluated using the Clinical Dehydration Scale (CDS),
assessing four items: general appearance, eyes, mucous
membranes, and tears [18]. Parents received a symptom
diary (see electronic supplementary material, online
resource 1) and were instructed to complete it, assessing
the number of stools, stool consistency according to
m-BSFS-C, food and liquid intake, adverse events, and
need for other therapies during the study period. All parents
were also instructed to determine the daily number of
stools. During the 24-, 48-, and 72-h evaluation, tolerance
to treatment, side effects, changes in concomitant medi-
cation, need for additional visits to the pediatrician or
emergency room, as well as data regarding the outcome of
the gastroenteritis (number of bowel movements per day
and consistency, vomiting, and weight) were monitored.
The duration of diarrhea was defined as the time in hours
from enrollment to the last abnormal (loose or liquid) stool.
Last abnormal stool was defined when the child passed
normal stool or no stool for the next 24 h. Stool consis-
tency was evaluated on m-BSFS-C and defined as follows:
(1) separate hard lumps, like nuts; (2) sausage-shaped but
lumpy; (3) like a sausage or snake, smooth and soft; (4)
fluffy pieces with ragged edges, a mushy stool; and (5)
watery, no solid pieces [16]. Therapeutic adherence was
evaluated on the basis of the number of doses received in
48 h of treatment; good compliance was defined as when
the patients received 75% or more of doses according to the
patient’s bodyweight.
At the last visit, on day 7, symptom diary, including side
effect occurrence, was evaluated.
The main objective of this study was to determine the
efficacy of treatment according to the number of bowel
movements after 48 and 72 h after initiation of therapy
with ORS ? G versus ORS alone. Secondary aims were to
evaluate differences in the length of the diarrhea, stool
characteristics, and the safety and tolerance to the study
drug.
The study protocol was defined in accordance with the
Declaration of Helsinki, and was approved by the ethical
committee of each participating center (593/12). Written
informed consent was obtained from parents of all children.
2.1 Statistical Analysis
All data were summarized and displayed as mean ± stan-
dard deviation (SD) for the continuous variables. Cate-
gorical data were expressed as frequencies and
percentages. Comparison of groups was performed using
Student’s t test for unpaired data in a two-group compar-
ison and one-way analysis of variance (ANOVA) with
Bonferroni’s test for multiple group comparisons. Chi-
square tests with Fisher’s correction were used to address
any differences for categorical variables, as needed. A
p value of 0.05 or less was considered as significant.
Assessment of the duration of diarrhea and specific vari-
ables was performed using Pearson and Spearman rank
correlation. Kaplan–Meier survival analysis was used to
estimate the survival distribution of the duration of diarrhea
in the two groups. GraphPad statistical package was used to
perform all statistical analyses (GraphPad Software, Inc.).
3 Results
Ninety-six children (42 males; median age 19.6 months,
age range 3–69 months) were initially recruited from June
2012 to June 2014: three were excluded because of con-
comitant chronic diseases; 19 were already receiving
racecadotril; one started antibiotic therapy; two who
received ORS needed intravenous rehydration; and 11
refused to take part in the study. Therefore, 60 children [30
males (50%); median age 18 months, age range
3–66 months] were included in the study (Fig. 1).
Patients were randomized as follows: 29 (median age
18 months; range 7–43 months) received an ORS; 31
children (median age 20 months; range 3–66 months)
received ORS ? G.
Both groups were similar in terms of baseline clinical
characteristics: median age, gender distribution, weight,
concomitant symptoms, and CDS (Table 1). Seventeen
patients in group 1 and 14 in group 2 self-managed their
toileting.
The number of bowel movements at enrollment was
5.1 ± 2.5 in the ORS group and 6.2 ± 2.9 in the ORS ? G
group (p = 0.11).
At 24 and 48 h, the number of bowel movements was
not significantly different between the two groups
(3.0 ± 1.1 ORS vs. 2.9 ± 1.0 ORS ? G; p = 0.81 and
3.2 ± 0.8 vs. 2.7 ± 1.3; p = 0.06, respectively). However,
at 72 h, children with ORS ? G had a significant reduction
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in bowel movements (1.0 ± 1.4) compared with those
treated with ORS (2.0 ± 1.8; p = 0.01) (Fig. 2). At 48 h, a
significant improvement in bowel consistency, according to
m-BSFS-C, was reported in the ORS ? G group compared
with the ORS group (3.7 ± 1.0 and 4.3 ± 0.8; p = 0.005).
The mean duration of diarrhea was significantly shorter
in patients treated with ORS ? G than in those treated with
ORS only (76.8 ± 19.2 vs. 108 ± 24.0 h; p\ 0.0001),
with a mean difference of 31.2 h. Figure 3 shows the time
to diarrhea resolution in the two groups (log-rank 5.7;
p = 0.01). In a univariate analysis of baseline clinical
variables related to the duration of diarrhea at 72 h, we
found age to be the only factor correlated [r = 0.26; 95%
confidence interval (CI) 0.01–0.48; p = 0.03] (Table 2).
After 72 h of treatment, 28 patients (96.5%) in the ORS
group and 29 (93.5%) in the ORS ? G group did not
complain of any symptoms: one child (3%) in the ORS
group and one (3%) in the ORS ? G complained of
Fig. 1 Consort flow diagram of
the two groups’ progress
through the phases of the
parallel randomized trial:
enrollment, intervention
allocation, follow-up, and data
analysis
Table 1 Baseline clinical
characteristics of the children
enrolled in the study
ORS group (N = 29) ORS ? G group (N = 31) p
Median age (range), months 18 (7–43) 20 (3–66) 0.14
Male (%) 15 (52) 15 (48) 1.0
Mean weight (kg ± SD) 10.77 ± 2.31 12.02 ± 3.27 0.09
Mean blood pressure (mmHg) Systolic: 102.3 ± 6.97 Systolic: 104.5 ± 9.02 0.86
Diastolic: 58.9 ± 3.14 Diastolic: 62.5 ± 5.22 0.77
Duration of diarrhea before enrollment (h) 79.9 55.0 0.12
Bowel movements/day 5.13 6.29 0.11
Abdominal pain (%) 8 (28) 15 (48) 0.11
Vomiting (%) 21 (72) 16 (52) 0.11
Fever (%) 18 (62) 14 (45) 0.20
Mean Clinical Dehydration Scale 3.10 3.26
Dehydration (%) Mild: 3 (10) Mild: 2 (6) 1.0
Moderate: 25 (86) Moderate: 26 (84) 0.47
Severe: 1 (4) Severe: 3 (10) 0.35
ORS oral rehydration solution, ORS ? G oral rehydration solution plus gelatin tannate, SD standard
deviation
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abdominal pain, and one in the ORS ? G group of vom-
iting. However, diarrhea was still present in seven patients
of the ORS group (24.1%) and in one patient of the
ORS ? G group (3.2%).
Three patients in the ORS group and one in the ORS ? G
group needed additional visits to the primary doctor during
treatment and one of the ORS group resorted to the emer-
gency room; all had diarrhea lasting more than 72 h.
All parents filled out the diary completely.
At 7-day follow-up, tolerability and drug acceptancewere
evaluated: all patients received 75% or more of the drug
doses according to the patient’s weight. One patient reported
the occurrence of nausea about 20 min after administration
of gelatin tannate. No other adverse events were reported.
4 Discussion
The most recent ESPGHAN guidelines for the treatment of
acute gastroenteritis clearly state that oral rehydration with
a hypo-osmolar solution is the main treatment and should
be started as soon as possible [2].
Recent data have highlighted and introduced the possi-
bility of using gelatin tannate, a mucosal barrier protector,
as an innovative approach in the management of intestinal
diseases, with the aim of enhancing mucus barrier activity
and restoring the gut barrier [11]. Nevertheless, there are
very limited data on its efficacy in children with acute
diarrhea, although a randomized controlled trial performed
in adults with acute gastroenteritis reported its good effi-
cacy and safety in this setting [14].
The objective of our single-blind, prospective, random-
ized, parallel study was to compare the efficacy of combined
therapy with gelatin tannate and oral rehydration with that of
oral rehydration alone in children younger than 6 years
affected with acute gastroenteritis as outpatient care.
We found patients treated with ORS ? G to have a
significant decrease in the number of bowel movements
after 72 h of treatment, when compared with those man-
aged with ORS alone, while no significant difference was
shown after 24 and 48 h, and a significant improvement of
bowel consistency was seen after 48 h of treatment.
Since it has already been demonstrated that gelatin tan-
nate exerts its action by restoring the physiological function
of the intestine, one may speculate that the drug is able to
provoke a clinical effect only after restoring the intestinal
barrier and thus will not be immediately effective [9, 11].
Furthermore, the slow action may be also due to the well-
Fig. 2 Mean of bowel movements per day. ORS ? G children had a
significant reduction in the bowel movements compared with those
treated with ORS only at 72 h. ORS oral rehydration solution,
ORS ? G oral rehydration solution plus gelatin tannate
Fig. 3 Kaplan–Meier analysis. The Kaplan–Meier estimator shows
the fraction of patients still affected by diarrhea after the start of
treatment. ORS oral rehydration solution, G ? ORS oral rehydration
solution plus gelatin tannate
Table 2 Univariate analysis of
baseline clinical factors related
to the persistence of diarrhea
after 3 days in 60 children with
acute gastroenteritis
r 95% CI P values
Age 0.26 0.01 to 0.48 0.03
Gender (male) 0.06 -0.19 to 0.31 0.60
Symptom duration at the enrollment 0.06 -0.19 to 0.30 0.64
Number of bowel movements -0.02 -0.27 to 0.23 0.85
Vomiting -0.15 -0.39 to 0.1 0.23
Abdominal pain 0.20 -0.05 to 0.43 0.11
Fever 0.11 -0.14 to 0.36 0.37
CI confidence interval
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known astringent properties of tannins allowing the
absorption of proinflammatory mucoproteins from the
intestinal mucus and their elimination through the feces [19].
Overall, the mean duration of diarrhea was significantly
shorter in patients treated with ORS ? G than in those
given ORS only, with a mean difference of 31.2 h. These
data are in keeping with the clinical effect of gelatin tan-
nate in adults and with previous studies on the efficacy of
other drugs suggested for the treatment of acute gastroen-
teritis [14]. Salazar-Lindo et al. reported a reduction in the
duration of diarrhea in racecadotril-treated children up to
44 h, compared with controls, while diosmectite is effec-
tive in reducing acute gastroenteritis by 23.39 h [7, 20].
Compliance with administration was good; every patient
received 75% or more of doses according to the patient’s
weight. This result confirms a good ease of administration.
Safety was similar for the two treatment groups, with only
one patient reporting the occurrence of nausea during a
single administration of gelatin tannate. Three patients in
the ORS group and one in the ORS ? G group needed
additional visits to the primary doctor during treatment,
and one in the ORS group needed additional evaluation at
the emergency room. These data suggest that duration of
illness could be an important reason to utilize primary care
or the emergency room.
We tried to identify predictive factors for prolonged
diarrhea, and we found only age to be significantly corre-
lated, with a duration of diarrhea greater than 3 days for
older compared with younger children. Conversely, a pre-
vious study conducted in developing countries reported
young age to be a risk factor for prolonged diarrhea [21].
This result could be related to the different study setting
and design and should be confirmed in larger trials.
The strengths of our study include adequate random-
ization and the use of intention-to-treat analysis, both of
which minimize the risk of bias. However, there are several
limitations. First of all, the small sample size. Baseline
characteristics were similar in the two groups of patients,
and patients were randomized according to a computer-
generated protocol with a single-blind design in order to
minimize the risk of bias.
Second, clinical measures (i.e., number of bowel
movements and duration of diarrhea) were used as out-
comes. These measures alone are not considered optimal,
indeed stool output is the main criterion defined by the
World Health Organization to conclude that a drug is
effective in acute diarrhea [22]. Since gelatin tannate was
used as outpatient therapy, we could not assess the 24 h
stool output, and we decided to evaluate clinical outcomes
of efficacy. We evaluated patients at 24, 48 and 72 h, and
we made an additional visit at day 7, in order to obtain
accurate data, and we used a symptom diary for the entire
duration of the study. Furthermore, we monitored common
clinical symptoms such as fever, vomiting, abdominal pain,
development of any other new symptoms and any hyper-
sensitivity reaction like skin rashes to define potential
adverse effects of intervention.
In contrast to other studies, we did not perform stool
cultures at baseline [20, 23]. Nevertheless, ESPGHAN does
not recommend performing stool cultures for acute gas-
troenteritis in primary healthcare, and we did not aim to
evaluate the impact of gelatin tannate based on the dif-
ferent etiologies of diarrhea [2]. Finally, in our study
design, patients were not hospitalized, the control group
did not receive a placebo, and there was no direct moni-
toring of drug administration.
5 Conclusions
In conclusion, the results of this study suggest that gelatin
tannate could be effective, well-tolerated, and safe in
addition to oral rehydration therapy in infants and children
with acute diarrhea. Further randomized, double-blind,
placebo-controlled studies are needed to confirm its effi-
cacy and safety and to evaluate its routine use in children
with acute gastroenteritis.
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